Neuroprotective properties of arylpiperazine-sulphonamides in an in vitro model of Parkinson’s disease
Objective: To investigate the neuroprotective effects of novel arylpiperazine compounds as measured by viability of SH-SY5Y cells in vitro. Background: Parkinson’s disease (PD) is a…Improvement in motor symptoms and quality of life in patients with an earlier stage of advanced Parkinson’s disease treated with foslevodopa/foscarbidopa subcutaneous 24 hour infusion
Objective: To evaluate whether treatment with foslevodopa/foscarbidopa (LDP/CDP), a continuous (24‑hour/day) subcutaneous infusion of carbidopa/levodopa prodrugs, improves motor fluctuations and quality of life (QoL) in…Istradefylline therapy for PD plus oromandibular dystonia
Objective: To clarify the dopaminergic system link between parkinson's disease (PD) and oromadibular dystonias (OMDy) co-occur, and the effect of istradefylline (IST) therapy. Background: OMDy are…Transcriptional dysregulation in iPSC-derived neurons from patients with X-linked dystonia-parkinsonism
Objective: We pursue to identify dysregulated cellular pathways underlying X-linked dystonia-parkinsonism (XDP) by transcriptome profiling of induced pluripotent stem cell (iPSC)-derived neuronal cultures from XDP…LRRK2 PROTAC® degrader molecules induce robust biomarker responses in preclinical in vivo pharmacology studies following acute and chronic oral dosing
Objective: Report on the non-clinical in vivo pharmacokinetic and pharmacodynamic biomarker response to PROteolysis TArgeting Chimera (PROTAC®) molecules designed to induce degradation of leucine rich…Network attack tolerance: A resilience proxy for Parkinson’s disease?
Objective: To investigate if individual capacity in network attack tolerance moderates the relationship between striatal dopamine loss and symptom severity in PD. Background: It was…Bone Health in Parkinson’s Disease
Objective: Optimise bone health in people with Parkinson’s Disease Background: People with Parkinson’s Disease (PD) have an increased risk of osteoporosis and associated fractures due…Widespread Synuclein pathology in hyposmics precedes dopamine transporter deficit in PARS
Objective: The Parkinson Associated Risk syndrome (PARS) study is designed to identify a Parkinson disease (PD) biomarker/clinical marker derived cohort enriched to develop typical symptoms…Effect of Sex on the association between GBA mutations and Cognitive Decline in Parkinson’s Disease
Objective: To assess the impact of sex and glucocerebrosidase (GBA) mutations on cognitive trajectories in a sample of Parkinson's disease (PD) patients. Background: Accumulating evidence…Parkinson’s Disease Hospital Optimization Project
Objective: To describe The Parkinson’s Disease Hospital Optimization Project (PD-HOP) that we established to optimize inpatient care and improve the hospital experience and outcomes for…
- « Previous Page
- 1
- …
- 574
- 575
- 576
- 577
- 578
- …
- 1942
- Next Page »